KALA BIO (KALA) Competitors $5.92 -0.08 (-1.33%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends KALA vs. JMAC, INMB, ADVM, CRDL, DERM, ANRO, IMUX, SKYE, CNTX, and AVTXShould you be buying KALA BIO stock or one of its competitors? The main competitors of KALA BIO include Maxpro Capital Acquisition (JMAC), INmune Bio (INMB), Adverum Biotechnologies (ADVM), Cardiol Therapeutics (CRDL), Journey Medical (DERM), Alto Neuroscience (ANRO), Immunic (IMUX), Skye Bioscience (SKYE), Context Therapeutics (CNTX), and Avalo Therapeutics (AVTX). These companies are all part of the "pharmaceutical products" industry. KALA BIO vs. Maxpro Capital Acquisition INmune Bio Adverum Biotechnologies Cardiol Therapeutics Journey Medical Alto Neuroscience Immunic Skye Bioscience Context Therapeutics Avalo Therapeutics Maxpro Capital Acquisition (NASDAQ:JMAC) and KALA BIO (NASDAQ:KALA) are both small-cap unclassified companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, valuation and community ranking. Do analysts rate JMAC or KALA? KALA BIO has a consensus price target of $15.00, suggesting a potential upside of 153.38%. Given KALA BIO's stronger consensus rating and higher probable upside, analysts plainly believe KALA BIO is more favorable than Maxpro Capital Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00KALA BIO 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, JMAC or KALA? Maxpro Capital Acquisition has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500. Comparatively, KALA BIO has a beta of -2.15, suggesting that its stock price is 315% less volatile than the S&P 500. Does the MarketBeat Community favor JMAC or KALA? KALA BIO received 300 more outperform votes than Maxpro Capital Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformMaxpro Capital AcquisitionN/AN/AKALA BIOOutperform Votes30066.82% Underperform Votes14933.18% Which has preferable valuation & earnings, JMAC or KALA? Maxpro Capital Acquisition has higher earnings, but lower revenue than KALA BIO. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaxpro Capital AcquisitionN/AN/AN/AN/AN/AKALA BIO$3.89M7.02-$42.20M-$12.47-0.47 Is JMAC or KALA more profitable? Maxpro Capital Acquisition's return on equity of 0.00% beat KALA BIO's return on equity.Company Net Margins Return on Equity Return on Assets Maxpro Capital AcquisitionN/A N/A N/A KALA BIO N/A -448.61%-69.37% Do insiders and institutionals hold more shares of JMAC or KALA? 73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 19.3% of Maxpro Capital Acquisition shares are owned by company insiders. Comparatively, 8.3% of KALA BIO shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media refer more to JMAC or KALA? In the previous week, Maxpro Capital Acquisition's average media sentiment score of 0.00 equaled KALA BIO'saverage media sentiment score. Company Overall Sentiment Maxpro Capital Acquisition Neutral KALA BIO Neutral SummaryMaxpro Capital Acquisition and KALA BIO tied by winning 5 of the 10 factors compared between the two stocks. Ad Paradigm Press Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!Click here now for the urgent details. Get KALA BIO News Delivered to You Automatically Sign up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KALA vs. The Competition Export to ExcelMetricKALA BIOPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.29M$6.57B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E Ratio-0.4710.4289.5817.17Price / Sales7.02195.801,116.12116.95Price / CashN/A57.1642.8237.86Price / Book2.125.094.774.78Net Income-$42.20M$151.83M$120.15M$225.60M7 Day Performance-4.21%-2.13%-1.92%-1.23%1 Month Performance-9.62%-3.10%11.47%3.36%1 Year Performance-14.82%11.54%30.54%16.60% KALA BIO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KALAKALA BIO3.8466 of 5 stars$5.92-1.3%$15.00+153.4%-13.3%$27.29M$3.89M-0.4730Gap DownJMACMaxpro Capital AcquisitionN/A$8.34+7.8%N/A+837.6%$112.00MN/A0.002,021Gap DownINMBINmune Bio1.4805 of 5 stars$5.05+6.3%$20.00+296.0%-55.7%$111.97M$42,000.00-2.1810ADVMAdverum Biotechnologies4.2094 of 5 stars$5.30-1.3%$27.83+425.2%-40.0%$110.25M$1M-0.90190Analyst DowngradeNews CoverageCRDLCardiol Therapeutics2.2579 of 5 stars$1.32-0.4%$8.75+560.4%+44.0%$108.25M$60,000.00-3.4120Analyst ForecastAnalyst RevisionNews CoverageGap DownDERMJourney Medical2.548 of 5 stars$4.99-2.0%$9.38+87.9%N/A$104.24M$79.18M-5.4190ANROAlto Neuroscience3.2563 of 5 stars$3.85+0.5%$20.00+419.5%N/A$103.83M$210,000.000.00N/AIMUXImmunic2.933 of 5 stars$1.15+1.3%$11.80+930.6%-20.6%$103.14MN/A-0.9270Positive NewsSKYESkye Bioscience2.1878 of 5 stars$3.38+0.9%$18.67+452.3%-10.6%$102.54MN/A0.0011News CoveragePositive NewsGap DownCNTXContext Therapeutics2.9747 of 5 stars$1.36-2.2%$6.80+400.0%+1.0%$102.00MN/A-1.477Positive NewsGap DownAVTXAvalo Therapeutics3.712 of 5 stars$9.80+6.2%N/A-13.7%$101.86M$820,000.000.0040Analyst ForecastNews Coverage Related Companies and Tools Related Companies Maxpro Capital Acquisition Competitors INmune Bio Competitors Adverum Biotechnologies Competitors Cardiol Therapeutics Competitors Journey Medical Competitors Alto Neuroscience Competitors Immunic Competitors Skye Bioscience Competitors Context Therapeutics Competitors Avalo Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KALA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KALA BIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KALA BIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KALA Stock Alerts